Autolus Announces Partial Exercise of Underwriters' Option to Purchase Additional ADSs
Autolus Therapeutics (Nasdaq: AUTL) announced on December 21, 2022, that underwriters have exercised a partial option to buy an additional 6,927,102 American Depositary Shares (ADSs) at $2.00 each. This move will yield roughly $13.9 million in gross proceeds, bringing the total raised from the public offering to approximately $163.9 million. The offering, which closed on December 13, 2022, involved a total of 81,927,102 ADSs sold. Jefferies LLC, William Blair & Company, and Wells Fargo Securities acted as joint bookrunners for the offering.
- Raised approximately $163.9 million through the public offering.
- Successful partial exercise of underwriters' option, enhancing liquidity.
- None.
LONDON, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today that the underwriters of its previously announced public offering of American Depositary Shares, or ADSs, which closed on December 13, 2022, have partially exercised their option to purchase an additional 6,927,102 ADSs, at a price per ADS of
Jefferies LLC, William Blair & Company L.L.C. and Wells Fargo Securities, LLC acted as joint bookrunners for the offering.
A preliminary prospectus supplement to the prospectus describing the terms of the offering was filed with the Securities and Exchange Commission, or the SEC, on December 8, 2022, and a final prospectus supplement was filed with the SEC on December 12, 2022. The offering of these ADSs is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement, which, for the avoidance of doubt, will not constitute a “prospectus” for the purposes of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European Economic Area. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained for free from the joint book-running managers for the offering, Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at prospectus@williamblair.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, New York, 10001, at 833-690-2713 or email a request to cmclientsupport@wellsfargo.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Contacts:
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
What is the recent public offering by Autolus (AUTL)?
How much did Autolus raise from the recent ADS offering?
What is the price per ADS in Autolus' recent offering?
Who were the underwriters for Autolus' public offering?
When did the public offering of Autolus close?
